Improved Activation toward Primary Colorectal Cancer Cells by Antigen-Specific Targeting Autologous Cytokine-Induced Killer Cells by Schlimper, Claudia et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2012, Article ID 238924, 8 pages
doi:10.1155/2012/238924
Research Article
ImprovedActivation toward Primary Colorectal
CancerCellsby Antigen-SpeciﬁcTargeting Autologous
Cytokine-InducedKillerCells
ClaudiaSchlimper,1 Andreas A. Hombach,2 Hinrich Abken,2,3
andI ng oG.H.Sc h m id t-W o l f 3,4
1Department of Neurosurgery, University of Bonn, 53127 Bonn, Germany
2Center for Molecular Medicine Cologne and Department I of Internal Medicine, University of Cologne, 53901 Cologne, Germany
3Center for Integrated Oncology Cologne-Bonn, Germany
4Department of Internal Medicine III, University Hospital Bonn, Sigmund-Freud-Straße 25, 53105 Bonn, Germany
Correspondence should be addressed to Ingo G. H. Schmidt-Wolf, picasso@uni-bonn.de
Received 2 September 2011; Revised 3 November 2011; Accepted 17 November 2011
Academic Editor: Ana Lepique
Copyright © 2012 Claudia Schlimper et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Adoptive therapy of malignant diseases with cytokine-induced killer (CIK) cells showed promise in a number of trials; the
activation of CIK cells from cancer patients towards their autologous cancer cells still needs to be improved. Here, we generated
CIK cells ex vivo from blood lymphocytes of colorectal cancer patients and engineered those cells with a chimeric antigen receptor
(CAR) with an antibody-deﬁned speciﬁcity for carcinoembryonic antigen (CEA). CIK cells thereby gained a new speciﬁcity as
deﬁned by the CAR and showed increase in activation towards CEA+ colon carcinoma cells, but less in presence of CEA− cells,
indicated by increased secretion of proinﬂammatory cytokines. Redirected CIK activation was superior by CAR-mediated CD28-
CD3ζ than CD3ζ signaling only. CAR-engineered CIK cells from colon carcinoma patients showed improved activation against
their autologous, primary carcinoma cells from biopsies resulting in more eﬃcient tumour cell lysis. We assume that adoptive
therapy with CAR-modiﬁed CIK cells shows improved selectivity in targeting autologous tumour lesions.
1.Introduction
Although a variety of therapeutic options for metastatic
colon cancer were evaluated during the last decade, most pa-
tients in advanced stages of the disease have no hope for cure
by standard therapies. Alternative therapeutic approaches
including immunotherapy are currently explored [1]. One of
the major pitfalls in the adoptive immunotherapy of cancer
is the strikingly low activation of T cells from cancer patients
compared to healthy donors due to reduced expression of
TCR/CD3 components [2]. The need for alternative eﬀector
cells in targeting colorectal carcinoma becomes obvious by
the fact that T cells inﬁltrating colon cancer metastases have
reduced CD3ζ chain expression and lack tumour-speciﬁc
activation [3]. Compared to ﬁrstly activated eﬀector T cells,
ex vivo generated cytokine-induced killer (CIK) cells have a
number of advantages since they exhibit properties diﬀerent
from eﬀector or central memory T cells, that is, CIK cells are
activated in an MHC-independent fashion [4, 5], produce
proinﬂammatory cytokines, mainly IFN-γ and IL-4 [6, 7],
and exhibit antigen-independent cytolytic activities against
a variety of tumour cells. CIK cells are generated ex vivo
by extensive stimulation of CD3+ CD56− CD8+ T cells with
IFN-γ and CD3 and prolonged propagation in presence of
high-dose IL-2 [4]. After 2-3 weeks in culture, the majority
of cells exhibit a large granular lymphocyte morphology
and express both NK and T-cell markers including CD8,
CD11a, CD49d, CD56, and NKG2D, while lacking most NK-
cell-associated activating and inhibitory receptors [8]. The
CD45RA+ CCR7− CD62L(+), CD27+, CD28−, MIF-1a+ CIK
phenotype coincides with that for terminally diﬀerentiated
memory T cells [9]. CIK cells display extraordinary cytolytic2 Clinical and Developmental Immunology
capacities toward a broad array of malignant cells [10]a n d
traﬃce ﬃciently to the tumour side after systemic delivery
[11].Uponactivation,CIKcellsupregulateperforinandFasL
as well as DAP10 which couples NKG2D signaling to per-
forin-based cytotoxicity [12], thereby recognizing a class of
stress-associated ligands, NKG2D ligands, expressed on the
tumour cell surface. Consequently, CIK cells exhibit MHC-
unrestricted cytotoxicity and do not rely on a particular an-
tigen. Based on these and other properties, CIK cells at-
tracted interest for adoptive immunotherapy particularly in
advanced stages of the disease where repression of MHC
expression or defects in the antigen-processing machinery
frequently occur. For application in adoptive therapy, CIK
cells display the advantage that they do not require priming
but can rapidly be expanded in culture [13] and are less asso-
ciatedwithgraft-versus-hostdiseasethanconventionaleﬀec-
tor T cells [14]. CIK cells have been adoptively transferred in
phase I trials to treat leukemia/lymphoma and various solid
tumours including hepatocellular carcinoma, colon carcino-
ma, astrocytoma, melanoma, and renal cell carcinoma [15–
17]. CIK therapy showed low toxicity [18], however, limited
therapeutic eﬃcacy; CIK therapy is consequently assumed
t or e q u i r el a r g en u m b e r so fC I Kc e l l st ob et r a n s f e r r e dt o
achieve eﬃcient tumour clearance.
In this situation, we asked to improve CIK cell activation
against autologous tumour cells. We therefore made use of
the concept to redirect T cells towards deﬁned target cells by
a recombinant chimeric antigen receptor (CAR) which is ex-
pressed on the surface of T cells and provides both antigen-
targeting speciﬁcity and T-cell activation [19]. The CAR in
the extracellular moiety is composed of a single-chain frag-
ment of variable region (scFv) antibody for target binding
and in the intracellular moiety of the CD3ζ signaling chain
to initiate T-cell activation upon binding. To furthermore
increase T-cell activation, the costimulatory CD28 endodo-
main was linked to CD3ζ in a combined signaling moiety
[20]. We here demonstrate that ex vivo generated CIK cells
from colon carcinoma patients can be engineered with a
tumour-speciﬁc CAR; such “designer” CIK cells increase
cytokine secretion and cytolysis when engaging autologous,
primary colon carcinoma cells. Data suggest such CAR-engi-
neered CIK cells to improve the antitumour response in the
adoptive immunotherapy of colon carcinoma.
2.MaterialsandMethods
2.1. Patient Characteristics and Evaluation. Patients with col-
orectal carcinoma were treated by surgery of the primary
tumour lesion. Approval of the local ethics committee was
obtained. Diagnosis of CEA+ colorectal carcinoma was con-
ﬁrmed by immunohistology in a pathology reference centre.
2.2. Cells, Cell Lines, and Reagents. T cells were isolated
from heparinized peripheral blood by Ficoll density centrif-
ugation. CIK cells were generated as previously described
[21]. In brief, nonadherent peripheral blood mononuclear
cells were stimulated in RPMI 1640 medium, 10% (v/v)
FCS, and 25mM HEPES with human recombinant IFN-γ
(1,000 U/mL; Roche Biochemicals, Mannheim, Germany).
After 24h, 50ng/mL OKT3 monoclonal antibody (mAb)
(Orthoclone; Cilag, Sulzbach, Germany), 100 U/mL IL-1β,
and 300 U/mL IL-2 (Roche, Mannheim, Germany) were
added. Cells were propagated in a density of 3×106 cells/mL
in presence of IL-2. Primary colon carcinoma cell cul-
tures were established from patients’ carcinoma specimens
obtained during surgery as described [22]. In brief, tissue
specimens were incubated in HBSS buﬀer containing 100
U/mL DNase I (Roche Biochemicals), 50 U/mL collagenase
III (Biochrom, Berlin, Germany), 150 U/mL hyaluronidase
(Sigma, Deisenhofen, Germany), and 0,08 U/mL insulin
(Hoechst, Bad Soden a. Ts., Germany) at 37◦C for 15min.
Cells in the supernatant were centrifuged for 5min at
400×g and erythrocytes eliminated by incubation in 10mL
“erythrocyte-lysis buﬀer” (8,29g/L NH4Cl, 1g/L KHCO3,
0,0371g/L EDTA) and for 15min. Cells were washed and re-
suspended in Leibovitz medium, 10% (v/v) FCS, 1mM L-
glutamine, 1x MEM vitamins, 2.5mg/mL transferrin, 1g/L
sodium bicarbonate, 1g/L glucose, 80U/mL insulin, and
10mg/mLgentamycin(allfromGibcoInvitrogen,Karlsruhe,
Germany). Cultures contaminated with ﬁbroblasts were
removed. Carcinoma cells grown in culture were monitored
for CEA expression by immunohistochemical analysis using
an anti-CEA mAb 1C3 (Abcam, Cambridge, MA) and a per-
oxidase-conjugated Fab anti-mouse Ab (1:50) (Roche Diag-
nostics) and visualized by 3-Amino-9-ethylcarbazole (AEC;
Sigma). 293T cells are human embryonic kidney cells that
expresstheSV40largeTantigen.LS174TisaCEA+ colorectal
carcinoma line (ATCC, CL-188), and Colo201 is a CEA−
adenocarcinoma line (ATCC CCL 224). OKT3 (ATCC CRL
8001) is a hybridoma cell line that produces the anti-CD3
mAb OKT3. 293T cells were propagated in DMEM medium
supplemented with 10% (v/v) FCS, and all other cell lines
were cultured in RPMI 1640 medium, 10% (v/v) FCS (all
Life Technologies, Paisly, UK). OKT3 monoclonal antibody
(mAb) was aﬃnity puriﬁed from hybridoma supernatants
utilizing goat anti-mouse IgG2a antibodies (Southern Bio-
technology, Birmingham, AL, USA) that were immobilized
on N-hydroxy-succinimid-ester-(NHS)-activated sepharose
(Amersham Biosciences, Freiburg, Germany). Human IgG1
antibodies and the phycoerythrin-(PE-)conjugated anti-
CD3 mAb UCHT1 were purchased from Dako, Hamburg,
Germany, and the goat antihuman IgG antibody and its
FITC- and PE-conjugated F(ab )2 derivatives from Southern
Biotechnology. The antihuman IFN-γ mAb NIB42 and the
biotinylated anti-human IFN-γ mAb 4S.B3 were purchased
from BD Bioscience, San Diego, CA, USA.
2.3. Engineering of CIK Cells and Receptor-Mediated Activa-
tion. The generation of the expression cassettes for the CEA-
speciﬁc CARs BW431/26-scFv-Fc-ζ (no. 439) and BW431/
26-scFv-Fc-CD28-ζ (no. 607) was previously described [20].
CIK cells were engineered with the CAR by retroviral gene
transfer, and CAR expression was identiﬁed by ﬂow cy-
tometry utilizing a PE- or FITC-conjugated F(ab )2 anti-
human IgG1 antibody (1μg/mL), which recognizes the CAR
extracellularIgG1Fcspacer,andtheanti-CD3mAb(UCHT-1,Clinical and Developmental Immunology 3
1:20). Flow cytometry was performed using an FAC-
Scan cytoﬂuorometer equipped with the CellQuest research
software (Becton Dickinson, Mountain View, CA, USA).
Engineered CIK cells were cocultivated in round bottom 96-
well microtiter plates (1.25−10 × 104 engineered cells/well)
with CEA+ and CEA− tumour cells (5 × 104 cells/well),
respectively. After 48hrs, culture supernatants were analyzed
by ELISA for IFN-γ.B r i e ﬂ y ,I F N - γ was bound to the
solid phase anti-human IFN-γ mAb NIB42 (1μg/mL) and
detected by the biotinylated anti-human IFN-γ mAb 4S.B3
(0.5μg/mL) (both from Pharmingen). The reaction prod-
uct was visualized by a peroxidase-streptavidin conjugate
(1:10,000) and ABTS (both from Roche Diagnostics).
2.4. Cytotoxicity Assay. Speciﬁc cytotoxicity of receptor-
grafted T cells against target cells was monitored by an
XTT-based colorimetric assay. Brieﬂy, XTT (2,3-bis(2-me-
thoxy-4-nitro-5sulphonyl)-5[(phenyl-amino)carbonyl]-2H-
tetrazolium hydroxide) reagent (1mg/mL) (“Cell Prolifer-
ation Kit II,” Roche Diagnostics) was added to the cells
and incubated for 30–90min at 37◦C. Reduction of XTT
to formazan by viable tumour cells was monitored color-
imetrically at an adsorbance wavelength of 450nm and a
reference wavelength of 650nm. Maximal reduction of XTT
was determined as the mean of wells containing tumour cells
only, and the background as the mean of wells containing
culturemediumonly.Thenonspeciﬁcformationoﬀormazan
due to the presence of eﬀector cells was determined from
triplicate wells containing eﬀector cells in the same number
as in the corresponding experimental wells. The cytotoxicity
towards tumour cells was calculated as follows: cytotoxicity
[%] = 100 −{[OD (exp. wells-corresponding number
of eﬀector cells)/OD (tumour cells without effectors −
medium)] × 100}.
2.5. ELISpot Assay. IFN-γ-producing cells were determined
using the human “IFN-γ ELISpot kit” (H¨ olzel, Cologne,
Germany). Peripheral blood lymphocytes (4×104 cells) were
plated on nitrocellulose 96-well plates (Millipore, Bedford,
MA) coated with anti-IFN-γ antibody. Cells were stimulated
either with phytohemagglutinin (10μg/mL, Sigma) or with
100Gy irradiated tumour cells (1 × 103 tumour cells per
4 ×104 CIK cells) for 48hrs. Bound IFN-γ was detected by a
biotinylated antibody and visualized by streptavidin alkaline
phosphatase and BCIP/NBT (BioRad, Munich, Germany) as
substrate. Spots were recorded using the Bioreader 2000 (Bio
Sys, Karben, Germany).
2.6. Statistical Analyses. Statistical analyses were performed
using the two-tailed Student’s t-test if not otherwise
described.
3. Results
CD3+ CD56+ CIK cells were generated in vitro from pe-
ripheral blood lymphocytes of a healthy donor by incuba-
tion with IFN-γ, IL-1beta, and the agonistic anti-CD3 mAb
OKT3 and propagated in the presence of IL-2 as previously
Table 1: Characterization of CIK cells.
Marker Positive cells (%)
CD3 98.6
CD4 22.1
CD8 67.8
CD14 0.0
CD33 9.3
CD56 31.7
HLA-DR 67.4
CIK cells were generated from peripheral blood lymphocytes from a healthy
donorasdescribedinSection 2.After2-3weeksofpropagation,cellsexpress
the phenotype of CD3+CD56+ CIK cells. Data of a representative CIK cell
induction are shown.
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Figure 1: CIK cells are equally activated upon binding to CEA+
and CEA− tumour cells. CIK cells (4 × 104 cells) generated from
blood lymphocytes of healthy donors were coincubated with CEA+
Colo205 or CEA− Colo201 tumour cells (103 tumour cells) for
48hrs. IFN-γ production was monitored by ELIspot analysis. Data
represent the mean ± standard error of the mean; a representative
experiment out of three is shown. ∗P<0.05.
described [21]. After 2-3 weeks, CIK cells showed their char-
acteristic repertoire of surface molecules (Table 1). CIK cells
are activated upon coincubation with CEA+ Colo205 and
CEA− Colo201 colon carcinoma cells, respectively, indicated
by the increase in the number of IFN-γ-secreting CIK cells
(Figure 1). Activation of CIK cells occurred equally upon
binding to CEA+ and CEA− tumour cells conﬁrming the
known property of CIK cells of antigen-independent antitu-
mour activation.
W ea s k e dt of u r t h e r m o r ei m p r o v eC I Kc e l la c t i v a t i o n
selectively towards CEA+ colorectal carcinoma cells by en-
gineering with a CEA-speciﬁc CAR. Therefore, CIK cells
were retrovirally transduced to express either the anti-CEA
CARBW431/26scFv-Fc-CD3ζ withtheCD3ζ oralternatively
the anti-CEA CAR BW431/26scFv-Fc-CD28-CD3ζ with the
combined CD28-CD3ζ signaling domain, both harboring
the same CEA binding domain (Figure 2(a)). Both CARs4 Clinical and Developmental Immunology
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Figure 2: Genetic engineering of CIK cells with CARs. (a) Schematic diagram of the expression cassettes coding for the CEA-speciﬁc
CAR BW431/26scFv-Fc-CD3ζ and BW431/26scFv-Fc-CD28-CD3ζ used in this study. (b) CIK cells were generated from mononuclear cells
and subsequently transduced by retroviral infection to express the anti-CEA CAR. Mock-transduced cells (w/o) served as controls. CAR
expression was recorded by ﬂow cytometry using the anti-CD3 antibody OKT3 and the anti-human IgG-Fc antibody which detects the CAR
extracellular IgG1 Fc spacer domain.
were eﬃciently expressed on the CIK cell surface as recorded
by ﬂow cytometry using an antibody directed towards the
CARextracellularIgG1Fcspacerdomain(Figure 2(b)).CAR
expression on engineered cells was similar on CIK cells from
healthy donors and from colorectal cancer patients.
In order to record antigen-redirected activation, CIK
cells with engineered anti-CEA CAR were coincubated with
CEA+ colon carcinoma cells and with CEA− carcinoma cells
as controls. CAR CIK cells increased IFN-γ secretion upon
coincubation with CEA+, but not upon co-incubation with
CEA− tumour cells, whereas CIK cells without CAR did not
increase IFN-γ secretion (Figure 3(a)). IFN-γ secretion was
more increased when CIK cells were activated by the CD28-
CD3ζ than the CD3ζ CAR. Moreover, redirected cytolytic
activity of CAR-engineered CIK cells towards CEA+ tumour
cells is increased compared to CIK cells without CAR. The
cytolytic activity towards CEA− tumour cells was not sub-
stantially altered by engineering with a CEA-speciﬁc CAR as
control. We conclude that CIK cells can speciﬁcally be im-
proved in activation by CAR engagement.
To conﬁrm antigen speciﬁcity in CAR-mediated CIK ac-
tivation, we blocked the CAR by incubation with the anti-
idiotypic antibody BW2064, which is directed toward the
BW431/26-scFvdomainforantigenbinding.Assummarized
in Figure 3(b),b o t hI F N - γ secretion and cytolysis of CAR
CIK cells were repressed in presence of the anti-idiotypic
mAb, whereas an isotype-matched IgG1 antibody of irrele-
vantspeciﬁcityhadnoeﬀect.Datademonstratethattheanti-
tumour activation of CIK cells is mediated by the engineered
CAR in a CEA-dependent fashion.
We now explored whether activation of CIK cells from
colorectal cancer patients toward their autologous tumour
cells can be improved by CAR-mediated engagement of tar-
get cells. Colorectal carcinoma cells were isolated from surgi-
cal specimens and conﬁrmed by immunostainings to express
CEA(datanotshown).Colorectalcarcinomacellswerecoin-
cubatedwithengineered autologousCIK cellswiththeCD3ζ
orthecombinedCD28-CD3ζ CAR.AssummarizedinFigure 4,
activation of CAR CIK cells is substantially increased against
autologous tumour cells compared to nonmodiﬁed CIK cells
of the same patient. Increase in IFN-γ secretion was higher
upon stimulation by the CD28-CD3ζ than by the CD3ζ
signaling CAR. Increased IFN-γ secretion is due to increased
numbers of activated CIK cells as indicated by the increased
numbers of IFN-γ-ELISpots. Activation is antigen speciﬁc
since the same CAR-engineered CIK cells did not increaseClinical and Developmental Immunology 5
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Figure 3: CAR engagement produces higher activation of engineered CIK cells toward colorectal carcinoma cells. (a) CIK cells were
engineered with the CEA-speciﬁc ζ or CD28-ζ CAR (1–10 × 104 CAR+ cells/well) and incubated for 48hrs with CEA+ LS174T and CEA−
Colo201 cells (5 × 104 cells/well). Mock-modiﬁed CIK cells without CAR (w/o) served as control. IFN-γ secreted by activated CIK cells into
the culture supernatants was recorded by ELISA (upper), and cytolysis of tumour cells was monitored using the XTT-based viability assay
(lower). ∗P<0.05 compared to nonmodiﬁed CIK cells (w/o). (b) To block the CEA-speciﬁc CAR binding domain, CIK cells with ζ CAR
were incubated in presence of the anti-idiotypic antibody BW2064, which binds to the CAR BW431/26-scFv domain, or with an isotype-
matched IgG1 control antibody of irrelevant speciﬁcity together with CEA+ LS174T tumour cells for 48hrs. IFN-γ secreted into the culture
supernatant and speciﬁc cytotoxicity toward LS174T cells were monitored. Data show a representative experiment out of three. ∗P<0.05.6 Clinical and Developmental Immunology
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Figure 4: Activation of CIK cells from cancer patients against autologous colon carcinoma cells. Primary colon carcinoma cells were isolated
from a colon carcinoma biopsy as described in Section 2 and cultured in vitro for short term. CIK cells from the same patient were generated
in vitro and engineered with the ζ and the CD28-ζ CAR. CIK cells were coincubated for 48hrs with the autologous CEA+ colon carcinoma
cells (4 × 104 CIK cells; 103 tumour cells). Secreted IFN-γ in the culture supernatant was monitored by ELISA. Data represent the means of
triplicates ± standard error of the mean. One representative experiment out of three is shown. ∗P<0.05.
IFN-γ secretion in presence of CEA− Colo201 cells (data
not shown). Taken together activation of CIK cells from col-
orectal cancer patients toward autologous tumour cells can
be improved by CAR engagement of target cells and is
furthermore increased by combined CD28-CD3ζ CAR sig-
naling.
4. Discussion
To improve CIK cell activation towards autologous tumour
cells, we here revealed that (i) CIK cells generated ex vivo
from peripheral blood lymphocytes can be engineered with
a CAR as a targeting and activating receptor, (ii) engineered
CIK cells increase activation upon CAR engagement which is
superior upon CD28-CD3ζ signaling, and (iii) redirected by
the CAR, CIK cells from tumour patients exhibit improved
activation towards autologous tumour cells. While CIK cells
recognize tumour cells in an antigen-independent fashion,
CAR-engineered CIK cells gain antigen speciﬁcity as deﬁned
bytheCARbindingdomain.CAR-engineeredCIKcellsshow
improved tumour speciﬁcity indicated by increased IFN-γ
secretion upon contact to CEA+ compared to CEA− tumour
cells, while nonmodiﬁed CIK cells do not increase IFN-γ
in presence of CEA+ compared to CEA− tumour cells. Im-
provedCIKcellactivationrequiresantigenengagementsince
activation is blocked by an anti-idiotypic antibody directed
against the CAR binding domain. While CIK cells are sus-
ceptible to CD3ζ signaling, furthermore increase in IFN-γ
secretion by designer CIK cells upon CD28-ζ CAR stimula-
tion likely contributes to improve antitumour activity in vivo
throughactivationofbystandercells.Cytolyticactivityispre-
dominantly mediated by perforin triggered by NKG2D in
CIK cells [12]; other mechanisms may additionally contrib-
ute since blocking of NKG2D did not completely eliminate
the cytotoxic activity of CIK cells [23].
To evaluate the speciﬁc situation in cancer patients, we
confronted CIK cells from a colon cancer patient with the
autologouscoloncancercellsfromabiopsyinvitro.Similarly
as CIK cells from a healthy donor, CAR-engineered CIK cells
from cancer patients showed improved activation against
autologoustumourcellsindicatedbyincreaseinIFN-γ secre-
tioncomparedtoCIKcellswithoutCAR.Previousreportsby
Sheen et al. [24]a n do u rg r o u p[ 25]d e m o n s t r a t e de ﬃcient
targeting of CD3+ eﬀector T cells from cancer patients to-
ward autologous colon carcinoma cells; CIK cells herewith
expandthepanelofeﬀectorcellssuitabletotargetautologous
tumour cells.
Soluble CEA in the serum of cancer patients, particularly
inadvancedstagesofthedisease,maypreventCAR-mediated
activation of engineered CIK cells by blocking the binding
domain. In the case of the BW431/26 scFv CAR domain,
we previously demonstrated that CEA in concentrations up
to 20μg/mL does not block CAR-mediated T-cell activation
and does not inhibit induction of cytolytic activities [26]. We
therefore do not expect that serum CEA interferes with the
activity of anti-CEA CAR-modiﬁed CIK cells in colorectal
cancer patients.
Given the insuﬃciencies in activating CIK cells and the
diﬃculties in generating suﬃcient quantities for clinical ap-
plications, improved CIK activation upon CAR signaling is
assumed to decrease the numbers of CIK cells required to
elicit a therapeutic response. Previous strategies to overcome
limitations in speciﬁc T-cell activation used bispeciﬁc anti-
bodieswhichtargetCD3oneﬀectorcellsandthetumour-as-
sociated antigen CA125, Her2/neu, or other tumour-associ-
ated antigens on tumour cells [27, 28]. Redirecting CIK cells
from patients with ovarian cancer with bispeciﬁc antibodies
increased lysis of primary ovarian cancer cells [27]. Most
recently, CIK cells were modiﬁed with a CD33-speciﬁc CAR
for targeting acute myeloid leukemia cells [29]a n dw i t hClinical and Developmental Immunology 7
a CD19-speciﬁc CAR with 4-1BB costimulatory signal for
targeting B-lineage acute lymphoblastic leukemia [29, 30].
5. Conclusion
CAR-mediated redirection of CIK cells from colon carci-
noma patients improves their activation towards autologous
tumour cells in an antigen-dependent fashion.
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